Oramed Pharmaceuticals
Oramed Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral formulations of injectable protein drugs — led by an oral insulin capsule (ORMD-0801) — using its proprietary Protein Oral Delivery (POD™) platform, and operating alongside a diversified portfolio of strategic biomedical investments.
- Company typePublic
- Founded2006
- HeadquartersNew York, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Oramed Pharmaceuticals does
Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) is a clinical-stage pharmaceutical company founded in 2006 that has developed a proprietary Protein Oral Delivery (POD™) platform — a formulation technology originating from over 30 years of research at Jerusalem's Hadassah Medical Center — designed to protect protein and peptide drugs through the gastrointestinal tract and enable oral administration of therapeutics normally delivered by injection. Its lead asset is ORMD-0801, an oral insulin capsule for Type 2 diabetes (and under evaluation for NASH), with a broader pipeline that includes ORMD-0901 (oral exenatide/GLP-1) and combination insulin/GLP-1 capsules, all protected by a multi-jurisdiction patent estate.
The company's revenue mechanics are unusual for a clinical-stage biotech: commercial product revenue is effectively absent, while reported earnings have been driven by financial engineering — primarily a $101.875M senior secured note to Scilex Holding Company (with attached warrants), a $36.9M strategic equity investment in Alpha Tau Medical, and a transformative 2026 transaction with Lifeward Ltd. in which Oramed transferred the POD technology for up to 49.99% equity in Lifeward plus milestone and royalty rights (4% on ReWalk franchise sales for up to 10 years). Distribution partnerships span China (HTIT, now terminated), South Korea (Medicox), and Mexico/Latin America (Genomma Lab JV via Oravax Medical), but forward commercialization of ORMD-0801 is now being pursued independently via a planned 60-patient US-based trial.
Operationally, Oramed runs a lean organization (11–50 employees) with corporate headquarters in New York and R&D anchored in Jerusalem. As of March 31, 2026, total cash and assets stood at approximately $270M, and the company reported $65M of net income for the nine months ended September 30, 2025, almost entirely attributable to investment gains and Scilex repayments rather than pharmaceutical sales. The investment thesis hinges on whether ORMD-0801 can be repositioned for regulatory success after the 2023 Phase 3 discontinuation, while the balance sheet and portfolio provide multi-year runway and optionality through strategic holdings in Scilex, Alpha Tau, and Lifeward.
Oramed Pharmaceuticals firmographics
Firmographics- Name
- Oramed Pharmaceuticals
- Legal name
- Oramed Pharmaceuticals Inc.
- Website
- https://oramed.com
- Company type
- Public
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Oramed Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral formulations of injectable protein drugs — led by an oral insulin capsule (ORMD-0801) — using its proprietary Protein Oral Delivery (POD™) platform, and operating alongside a diversified portfolio of strategic biomedical investments.
- Ownership category
- akta.pro rank
Oramed Pharmaceuticals industry classification
Industry- Product category
- Oral Insulin and Diabetes Therapeutics
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)
Keywords
Where Oramed Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Oramed Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Strategic Investment Returns: Oramed generates returns through investments in biomedical companies including Scilex Holdings (loan repayments with interest), Alpha Tau Medical (equity appreciation), BioXcel Therapeutics, and Pelthos Therapeutics. The company received approximately $118 million in Scilex repayments as of early 2026 with expected total recovery of ~$161 million on original $99.5 million loan.
- Warrant and Equity Holdings: Oramed holds warrants to purchase Scilex shares (originally 6.5 million warrants at $0.01 exercise price) and receives proceeds from warrant repurchases. Also holds 49.9% beneficial ownership stake in Lifeward and ~14.1 million shares in Alpha Tau Medical valued at approximately $167 million.
- Technology Licensing and Royalties: Oramed licenses its POD technology to partners. Royalty arrangement with Lifeward includes 4% royalties on ReWalk franchise net sales for up to 10 years. Distribution agreements with Medicox (South Korea) and potential China commercialization via HTIT.
- Pharmaceutical Development: Core business of developing oral delivery formulations for injectable drugs. Revenue potential from FDA-approved oral insulin (ORMD-0801) targeting the $600+ billion injectable drugs market.
Go-to-market motion3 records
Distribution channels6 records
Marketing channels5 records
Oramed Pharmaceuticals product offering
Product offeringCore offering
Oramed is a clinical-stage pharmaceutical company developing its proprietary Protein Oral Delivery (POD™) platform technology, which enables oral administration of drugs currently delivered by injection. Its lead clinical candidates are ORMD-0801, an oral insulin capsule targeting Type 2 diabetes (and under evaluation for NASH), and ORMD-0901, an oral GLP-1 analog (exenatide) capsule. The company also licenses/transfer the POD platform to partners (e.g., Lifeward, HTIT, Medicox, Genomma Lab) and holds strategic biomedical investments in companies such as Scilex Holding and Alpha Tau Medical.
Product overview
Oramed Pharmaceuticals is a clinical-stage pharmaceutical company and platform technology pioneer in oral delivery solutions for drugs currently delivered via injection. The company operates a platform-plus-products model centered on its proprietary Protein Oral Delivery (POD™) technology. The core product portfolio includes ORMD-0801 (oral insulin capsule for Type 2 diabetes and NASH treatment) and ORMD-0901 (oral GLP-1 analog capsule), both leveraging the POD platform. The company has undergone strategic transformation, having transferred its POD technology to Lifeward while maintaining responsibility for the POD clinical program. Oramed maintains strategic investments in biomedical firms including Scilex Holdings, Alpha Tau Medical, and maintains a joint venture relationship with Hefei Tianhui Biotech (HTIT) for oral insulin development in China.
Differentiator
Problem solved
Functional benefit
Brands
- POD (Protein Oral Delivery): Oramed's novel Protein Oral Delivery technology designed to protect drug integrity and increase absorption for oral administration of injectable drugs.
Products and services
- ORMD-0801 (Oral Insulin Capsule) Oral insulin capsule candidate intended to be the first commercial oral insulin for treatment of Type 2 diabetes (with additional evaluation for Type 1 diabetes and NASH); based on POD™ technology to protect drug integrity and increase absorption across the gastrointestinal tract. Phase 2b data showed a 0.81% placebo-adjusted A1C reduction at 8mg dose (p=0.028) with no serious drug-related adverse events, hypoglycemia, or weight gain.
- ORMD-0901 (Oral GLP-1 Analog / Exenatide Capsule) Oral GLP-1 analog (exenatide) capsule for diabetes treatment with potential weight-loss benefits, leveraging the POD™ technology platform. Protected by a granted U.S. patent for oral administration of exenatide.
- Protein Oral Delivery (POD™) Technology Platform — Licensing Proprietary Protein Oral Delivery (POD™) platform technology licensed and transferred to commercialization partners (e.g., Lifeward globally) for oral administration of proteins and peptides historically delivered by injection. Protected by granted U.S., European, and international patents covering oral insulin, oral exenatide, and combination insulin+GLP-1 capsules.
Quantifiable outcome
- 0.81% placebo-adjusted A1C reduction at 8mg once daily dose (p=0.028)
- +3 more outcomes
Companies that use Oramed Pharmaceuticals
Customer profileSegments4 records
Ideal customer profiles2 records
Oramed Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Oramed Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and regional.
- Lifeward Ltd.coreStrategic partnership where Oramed transferred its clinical-stage Protein Oral Delivery (POD) technology to Lifeward, receiving up to 49.99% equity ownership in return. Deal valued at up to $47 million through equity, convertible notes, milestone-based funding, and warrant coverage. Oramed retains responsibility for POD clinical program including planned 60-patient U.S. trial for ORMD-0801. Oramed also receives 4% royalties on ReWalk franchise net sales for up to 10 years.
- Hefei Tianhui Biotech Co. Ltd. (HTIT)coreJoint venture with Chinese partner HTIT for oral insulin development and commercialization. HTIT completed Phase 3 oral insulin trials in China and submitted Marketing Authorization Application to NMPA. HTIT committed $70 million in cash to the JV while Oramed invested $25 million in cash and stock. Oramed terminated the joint venture in 2025 to proceed independently with its oral insulin program.
- MedicoxregionalDistribution agreement with Medicox for commercialization of oral insulin in South Korea. Oramed signed definitive deal for oral insulin distribution through Medicox's established pharmaceutical distribution network.
- Genomma Lab InternacionalregionalJoint venture between Oramed's subsidiary Oravax Medical and Genomma Lab for development and commercialization of oral COVID-19 vaccine in Mexico and Latin America. Genomma Lab brings local market expertise and distribution capabilities.
- Hadassah Medical CentercorePOD technology based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center. The research partnership provides the foundational scientific basis for Oramed's oral delivery platform technology.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Oramed Pharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- Sanofi: Major insulin manufacturer (Lantus, Toujeo, Apidra) with established global diabetes infrastructure. Sanofi represents incumbent competition for any oral insulin entrant and has the resources to develop or acquire competing oral delivery technology.
- Novo Nordisk: Global leader in diabetes care with dominant insulin and GLP-1 franchises (Ozempic, Wegovy, Rybelsus — the only currently approved oral GLP-1). Novo Nordisk is the primary competitive incumbent Oramed would face in any oral insulin or oral GLP-1 launch.
- Eli Lilly: Major diabetes/obesity player with injectable insulin and the leading injectable GLP-1 franchise (Mounjaro/Zepbound). Lilly's scale, manufacturing, and commercial reach make it a direct competitive threat to any oral diabetes entrant.
Emerging players
- Diasome Pharmaceuticals: Clinical-stage company developing oral hepatic-directed vesicle (HDV) insulin and other liver-targeted therapies for diabetes. Diasome is an emerging player working on alternative oral insulin delivery approaches with comparable patient target.
- Zealand Pharma: Clinical-stage peptide therapeutics company developing long-acting GLP-1 analogs and other peptide-based treatments. Zealand Pharma is an emerging peer in the GLP-1 space, directly relevant to Oramed's ORMD-0901 oral exenatide program.
- Intarcia Therapeutics: Developed an implantable osmotic pump for continuous delivery of diabetes therapies, representing another approach to reducing injection burden. Intarcia is a thematically comparable emerging peer in long-acting / non-injectable diabetes delivery.
- Biocon Biologics: India-based biosimilar insulin and biologic manufacturer with growing global commercial reach. Biocon is an emerging peer in the broader insulin market and a potential strategic partner or competitor for affordable insulin analogs.
- vTv Therapeutics: Clinical-stage company developing orally bioavailable small molecules for type 1 diabetes (TTP399) and other metabolic diseases. vTv is an emerging peer in oral diabetes therapeutics, though pursuing a different mechanism than peptide delivery.
Direct peers
- Adocia: French clinical-stage biotech developing oral formulations of insulin and GLP-1 analogs using BioChaperone technology. Adocia is the closest direct competitor in oral peptide delivery; Oramed's VP of Medical Affairs (Dr. Simon Bruce) was formerly CMO of Adocia.
- MannKind Corporation: Developed and commercializes Afrezza, an inhaled insulin, addressing the same unmet need Oramed targets: reducing the injection burden for diabetes patients. MannKind is a directly comparable non-invasive insulin delivery peer.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Oramed Pharmaceuticals social profiles
Digital presenceOramed Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Oramed Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles15 records
Oramed Pharmaceuticals subsidiaries and ownership
Company hierarchySubsidiaries3 records
Oramed Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds8 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Oramed Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments4 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Oramed Pharmaceuticals
What does Oramed Pharmaceuticals do?
Oramed is a clinical-stage pharmaceutical company developing its proprietary Protein Oral Delivery (POD™) platform technology, which enables oral administration of drugs currently delivered by injection. Its lead clinical candidates are ORMD-0801, an oral insulin capsule targeting Type 2 diabetes (and under evaluation for NASH), and ORMD-0901, an oral GLP-1 analog (exenatide) capsule. The company also licenses/transfer the POD platform to partners (e.g., Lifeward, HTIT, Medicox, Genomma Lab) and holds strategic biomedical investments in companies such as Scilex Holding and Alpha Tau Medical.
Is Oramed Pharmaceuticals a public or private company?
Oramed Pharmaceuticals is a public company. It is classified as public and is currently operating.
When was Oramed Pharmaceuticals founded?
Oramed Pharmaceuticals was founded in 2006. It employs 11 to 50 people.
Where is Oramed Pharmaceuticals based?
Oramed Pharmaceuticals is headquartered in New York, United States, in the North America region.
How does Oramed Pharmaceuticals make money?
Four revenue lines are on record. Strategic Investment Returns are the primary driver. The others are warrant and Equity Holdings, technology Licensing and Royalties and pharmaceutical Development.
Who are Oramed Pharmaceuticals's main competitors?
Broad incumbents on record are Sanofi, Novo Nordisk and Eli Lilly. Emerging players are Diasome Pharmaceuticals, Zealand Pharma, Intarcia Therapeutics, Biocon Biologics and vTv Therapeutics. Direct peers are Adocia and MannKind Corporation.
Does Oramed Pharmaceuticals have an API?
No public API is recorded for Oramed Pharmaceuticals.
What industry is Oramed Pharmaceuticals in?
Oramed Pharmaceuticals's product category is Oral Insulin and Diabetes Therapeutics. Its primary akta.pro industry code is HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325412 and its SIC code is 2834.